Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the attached request for loss of share certificate from the claimant.
21-03-2022

AstraZeneca Covid drug neutralises Omicron sub-variants in lab study

 Evusheld was tested against the BA.1, BA.1.1, and BA.2 sub-variants of Omicron and it was also shown in the study to limit inflammation in the lungs - a critical symptom in severe Covid-19 infections
21-03-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Closure of Trading Window

 This is to inform you that, in accordance with the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the Shares of the Company shall be closed from March 16, 2022 and the same shall reopen after 48 hours from the declaration of Audited Financial Results of the Company for the quarter and year ending March 31, 2022.
16-03-2022

Europe begins reviewing application for AstraZeneca COVID drug

 Infections from COVID-19 are still rising in parts of the world including Europe.
16-03-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith Certificate dated March 5, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
11-03-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers.
25-02-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

 We are enclosing herewith the Postal Ballot Notice dated February 8, 2022 being sent to the Members of the Company to their registered email address, seeking approval of the members for the special business as set out therein. The Notice is being sent to the Members whose names appear in the Register of Members/ Record of Depositories as on the cut-off date being Friday, February 18, 2022. The e-voting period commences on Monday, February 28, 2022 (9:00 am IST) and ends on Tuesday, March 29, 2022 (05:00 pm IST). The Company has engaged the National Securities Depository Limited for facilitating e-voting in a secure manner. The said information is also being made available on the website of the Company i.e. www.astrazeneca.com/india.
23-02-2022

Short AstraZeneca shelf life complicates vaccine rollout to world's poorest

 Many more vaccines are expected to be rejected as African nations and Covax said that from January they would not accept vaccines with less than two-and-a-half months' shelf life
16-02-2022
Bigul

ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing a copy of newspaper advertisement published in Business Standard and Prajavani newspapers.
15-02-2022

AstraZeneca swung to 4Q loss despite revenue rise; expects $2.1 bln restructuring charge

 The Anglo-Swedish pharma giant posted a net loss of $347 million for the last quarter of the year compared with a net profit of $1.01 billion the year prior
10-02-2022
Next Page
Close

Let's Open Free Demat Account